Ge Healthcare Technologies Inc. (GEHC)

$75.97

+1.23

(+1.65%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on Ge Healthcare Technologies Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.20B → 4.65B (in $), with an average decrease of 10.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 403.0M → 374.0M (in $), with an average decrease of 7.2% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 27.3% return, outperforming this stock by 29.6%

Performance

  • $75.01
    $76.22
    $75.97
    downward going graph

    1.26%

    Downside

    Day's Volatility :1.59%

    Upside

    0.33%

    downward going graph
  • $62.28
    $94.43
    $75.97
    downward going graph

    18.02%

    Downside

    52 Weeks Volatility :34.05%

    Upside

    19.55%

    downward going graph

Returns

PeriodGe Healthcare Technologies Inc.Index (NASDAQ Composite)
3 Months
-14.14%
8.8%
6 Months
2.41%
19.5%
1 Year
-2.34%
29.7%
3 Years
25.59%
25.2%

Highlights

Market Capitalization
34.6B
Book Value
$16.23
Dividend Share
0.12
Dividend Yield
0.16%
Earnings Per Share (EPS)
3.39
PE Ratio
22.36
PEG Ratio
20.11
Wall Street Target Price
92.74
Profit Margin
8.05%
Operating Margin TTM
13.85%
Return On Assets TTM
5.63%
Return On Equity TTM
22.39%
Revenue TTM
19.5B
Revenue Per Share TTM
42.8
Quarterly Revenue Growth YOY
-1.2%
Gross Profit TTM
7.2B
EBITDA
3.5B
Diluted Eps TTM
3.39
Quarterly Earnings Growth YOY
0.98
EPS Estimate Current Year
4.27
EPS Estimate Next Year
4.76
EPS Estimate Current Quarter
0.91
EPS Estimate Next Quarter
1.01

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Ge Healthcare Technologies Inc.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
7
7
6
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 22.07%

Current $75.97
Target $92.74

Company Financials

FY19Y/Y Change
Revenue
16.6B
-
Net Income
1.5B
-
Net Profit Margin
9.16%
-
FY20Y/Y Change
Revenue
17.2B
↑ 3.19%
Net Income
2.1B
↑ 35.04%
Net Profit Margin
11.99%
↑ 2.83%
FY21Y/Y Change
Revenue
17.6B
↑ 2.45%
Net Income
2.2B
↑ 9.18%
Net Profit Margin
12.78%
↑ 0.79%
FY22Y/Y Change
Revenue
18.3B
↑ 4.3%
Net Income
1.9B
↓ 14.73%
Net Profit Margin
10.45%
↓ 2.33%
FY23Y/Y Change
Revenue
19.6B
↑ 6.6%
Net Income
3.1B
↑ 62.0%
Net Profit Margin
15.88%
↑ 5.43%
Q4 FY22Q/Q Change
Revenue
4.9B
↑ 7.91%
Net Income
554.0M
↑ 13.52%
Net Profit Margin
11.22%
↑ 0.56%
Q1 FY23Q/Q Change
Revenue
4.7B
↓ 4.68%
Net Income
372.0M
↓ 32.85%
Net Profit Margin
7.9%
↓ 3.32%
Q2 FY23Q/Q Change
Revenue
4.8B
↑ 2.34%
Net Income
418.0M
↑ 12.37%
Net Profit Margin
8.68%
↑ 0.78%
Q3 FY23Q/Q Change
Revenue
4.8B
↑ 0.1%
Net Income
375.0M
↓ 10.29%
Net Profit Margin
7.78%
↓ 0.9%
Q4 FY23Q/Q Change
Revenue
5.2B
↑ 7.96%
Net Income
403.0M
↑ 7.47%
Net Profit Margin
7.74%
↓ 0.04%
Q1 FY24Q/Q Change
Revenue
4.7B
↓ 10.68%
Net Income
374.0M
↓ 7.2%
Net Profit Margin
8.04%
↑ 0.3%
FY20Y/Y Change
Total Assets
24.2B
-
Total Liabilities
9.5B
-
FY21Y/Y Change
Total Assets
26.3B
↑ 8.59%
Total Liabilities
9.6B
↑ 1.64%
FY22Y/Y Change
Total Assets
27.5B
↑ 4.68%
Total Liabilities
18.2B
↑ 88.71%
FY23Y/Y Change
Total Assets
32.5B
↑ 17.85%
Total Liabilities
25.1B
↑ 38.33%
Q4 FY22Q/Q Change
Total Assets
27.5B
↑ 5.65%
Total Liabilities
18.2B
↑ 97.81%
Q1 FY23Q/Q Change
Total Assets
32.6B
↑ 18.51%
Total Liabilities
25.9B
↑ 42.71%
Q2 FY23Q/Q Change
Total Assets
32.3B
↓ 1.0%
Total Liabilities
25.0B
↓ 3.67%
Q3 FY23Q/Q Change
Total Assets
32.4B
↑ 0.22%
Total Liabilities
25.2B
↑ 1.01%
Q4 FY23Q/Q Change
Total Assets
32.5B
↑ 0.22%
Total Liabilities
25.1B
↓ 0.38%
Q1 FY24Q/Q Change
Total Assets
32.2B
↓ 0.76%
Total Liabilities
24.6B
↓ 2.13%
FY19Y/Y Change
Operating Cash Flow
2.0B
-
Investing Cash Flow
-325.0M
-
Financing Cash Flow
-1.6B
-
FY20Y/Y Change
Operating Cash Flow
1.7B
↓ 15.18%
Investing Cash Flow
-323.0M
↓ 0.62%
Financing Cash Flow
-21.5B
↑ 1268.74%
FY21Y/Y Change
Operating Cash Flow
1.6B
↓ 4.74%
Investing Cash Flow
-1.8B
↑ 445.2%
Financing Cash Flow
-263.0M
↓ 98.78%
FY22Y/Y Change
Operating Cash Flow
2.1B
↑ 31.49%
Investing Cash Flow
-398.0M
↓ 77.4%
Financing Cash Flow
-822.0M
↑ 212.55%
Q1 FY23Q/Q Change
Operating Cash Flow
468.0M
↓ 55.09%
Investing Cash Flow
-266.0M
-
Financing Cash Flow
673.0M
↓ 1918.92%
Q2 FY23Q/Q Change
Operating Cash Flow
-67.0M
↓ 114.32%
Investing Cash Flow
-84.0M
↓ 68.42%
Financing Cash Flow
-227.0M
↓ 133.73%

Technicals Summary

Sell

Neutral

Buy

Ge Healthcare Technologies Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-6.24%
2.41%
-2.34%
25.59%
25.59%
Solventum Corp
Solventum Corp
-11.05%
-18.73%
-18.73%
-18.73%
-18.73%
Veeva Systems Inc.
Veeva Systems Inc.
-7.33%
6.51%
-1.02%
-37.84%
13.58%
Healthequity Inc
Healthequity Inc
7.38%
22.68%
27.35%
7.88%
16.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
22.36
22.36
20.11
4.27
0.22
0.06
0.0
16.23
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
55.46
55.46
1.35
4.76
0.13
0.06
NA
30.25
Healthequity Inc
Healthequity Inc
94.47
94.47
2.29
2.19
0.04
0.03
NA
24.11
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$34.6B
25.59%
22.36
8.05%
Solventum Corp
Solventum Corp
Hold
$10.8B
-18.73%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$30.4B
13.58%
55.46
22.34%
Healthequity Inc
Healthequity Inc
Buy
$7.6B
16.12%
94.47
7.71%

Corporate Announcements

  • Ge Healthcare Technologies Inc. Dividends March,2024

    In the quarter ending March,2024. Ge Healthcare Technologies Inc. has declared dividend of $0.03

    Read More

Company Information

ge healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i

Organization
Ge Healthcare Technologies Inc.
Employees
51000
CEO
Mr. Peter J. Arduini
Industry
Healthcare

FAQs